Background: The number of patients receiving renal replacement therapy (RRT) increases annually and worldwide. Differences in the RRT incidence, prevalence, and modality vary between regions and countries for reasons yet to be clarified. Aims: Gain a better understanding of the association between hemodialysis (HD)-related variables and general population global health indicators. Methods: The present study included prevalent HD patients from 27 countries/regions from the monitoring dialysis outcomes (MONDO) database from 2006-2011. Global population health indicators were obtained from the 2014 World Health Organization report and the Human Development Index from the Human Development Report Office 2014. The Spearman rank test was used to assess the correlations between population social economic indicators and HD variables. Results: A total of 84,796 prevalent HD patients were included. Their mean age was 63 (country mean 52-71), and 60% were males (country mean 52-85%). Significant correlations were found between HD demographic clusters and population education, wealth, mortality, and health indicators. The cluster of nutrition and inflammation variables were also highly correlated with population mortality, wealth, and health indicators. Finally, cardiovascular, fluid management, and dialysis adequacy clusters were associated with education, wealth, and health care resource indicators. Conclusion: We identified socioeconomic indicators that were correlated with dialysis variables. This hypothesis-generating study may be helpful in the analysis of how global health indicators may interfere with access to HD, treatment provision, dialytic treatment characteristics, and outcomes.

Keywords:
Health indicators, Hemodialysis, End-stage renal disease, Renal replacement therapy
1.
Annual Data Report. United States Renal Data System (USRDS) 2013: Chapter 11-13.
2.
ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2012. Academic Medical Center, Department of Medical Informatics, Amsterdam, the Netherlands, 2014.
3.
Cusumano AM, Garcia-Garcia G, Gonzalez-Bedat MC, Marinovich S, Lugon J, Poblete-Badal H, Elgueta S, Gomez R, Hernandez-Fonseca F, Almaguer M, Rodriguez-Manzano S, Freire N, Luna-Guerra J, Rodriguez G, Bochicchio T, Cuero C, Cuevas D, Pereda C, Carlini R: Latin American Dialysis and Transplant Registry: 2008 prevalence and incidence of end-stage renal disease and correlation with socioeconomic indexes. Kidney Int Suppl 2013;3:153-156.
4.
Pisoni RL, Greenwood RN: Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 2005;149:58-68.
5.
Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13:S37-S40.
6.
Moeller S, Gioberge S, Brown G: ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002;17:2071-2076.
7.
Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593.
8.
Grassmann A, Gioberge S, Moeller S, Brown G: End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006;30:895-897.
9.
Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, et al: Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J 2014;7:431-436.
10.
Jager KJ, Korevaar JC, Dekker FW, et al: The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis 2004;43:891-899.
11.
Chugh KS, Jha V, Chugh S: Economics of dialysis and renal transplantation in the developing world. Transplant Proc 1999;31:3275-3277.
12.
Caskey FJ, Kramer A, Elliott RF, Stel VS, Covic A, Cusumano A, Geue C, MacLeod AM, Zwinderman AH, Stengel B, Jager KJ: Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 2011;26:2604-2610.
13.
Yoshino M, Kuhlmann MK, Kotanko P, et al: International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006;17:3510-3519.
14.
Caskey FJ, Stel VS, Elliott RF, et al: The EVEREST study: an international collaboration. NDT Plus 2010;3:28-36.
15.
Caskey FJ, Jager KJ: A population approach to renal replacement therapy epidemiology: lessons from the EVEREST study. Nephrol Dial Transplant 2014;29:1494-1499.
16.
van de Luijtgaarden MW, Jager KJ, Stel VS, Kramer A, Cusumano A, Elliott RF, Geue C, MacLeod AM, Stengel B, Covic A, Caskey FJ: Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant 2013;28:1264-1275.
17.
Chugh KS, Jha V: Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int Suppl 1995;50:S7-S15.
18.
Nissenson AR, Prichard SS, Cheng IK, Gokal R, Kubota M, Maiorca R, Riella MC, Rottembourg J, Stewart JH: ESRD modality selection into the 21st century: the importance of non medical factors. ASAIO J 1997;43:143-150.
19.
Usvyat LA, Haviv YS, Etter M, Kooman J, Marcelli D, Marelli C, Power A, Toffelmire T, Wang Y, Kotanko P: The MONitoring Dialysis Outcomes (MONDO) initiative. Blood Purif 2013;35:37-48.
20.
von Gersdorff GD, Usvyat L, Marcelli D, Grassmann A, Marelli C, Etter M, Kooman JP, Power A, Toffelmire T, Haviv YS, Guinsburg A, Barth C, Schaller M, Bayh I, Scatizzi L, Tashman A, Thijssen S, Levin NW, van der Sande FM, Pusey C, Wang Y, Kotanko P: Monitoring dialysis outcomes across the world - the MONDO Global Database Consortium. Blood Purif 2013;36:165-172.
21.
World Health Statistics - Part III: Global Health Indicators. World Health Organization, 2014, pp 56-175.
22.
Khalid Malik, et al: Human Development Report 2014 - Sustaining Human Progress: Reducing Vulnerabilities and Building Resilience. United Nations Development Program, 2014.
23.
Martinsson A, Andersson C, Andell P, Koul S, Engström G, Smith JG: Anemia in the general population: prevalence, clinical correlates and prognostic impact. Eur J Epidemiol 2014;29:489-498.
24.
De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14:31-41.
25.
Nutrition in Chronic Renal Failure - KDOQI guideline. Am J Kidney Dis 2000;35(suppl 2):S9-S1022.
26.
Usvyat LA, Barth C, Bayh I, Etter M, von Gersdorff GD, Grassmann A, Guinsburg AM, Lam M, Marcelli D, Marelli C, Scatizzi L, Schaller M, Tashman A, Toffelmire T, Thijssen S, Kooman JP, van der Sande FM, Levin NW, Wang Y, Kotanko P: Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death. Kidney Int 2013;84:149-157.
27.
Wanner C, Tonelli M; Kidney Disease; Improving Global Outcomes Lipid Guideline Development Work Group Members: KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014;85:1303-1309.
28.
K/DOQI Workgroup: K/DOQI Clinical Practices Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005;45(suppl 3):S1-S153.
29.
Martinsson A, Andersson C, Andell P, Koul S, Engström G, Smith JG: Anemia in the general population: prevalence, clinical correlates and prognostic impact. Eur J Epidemiol 2014;29:489-498.
30.
Handelman GJ, Kotanko P, Cisternas MG, et al: Hospitalization and mortality in hemodialysis patients: association with hemoglobin variability. Blood Purif 2013;35:247-257.
31.
KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
32.
Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH, Eknoyan G: Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008;74:1237-1240.
33.
de Moraes PT, Figueiredo AE, Campos LG, Olandoski M, Barretti P, Pecoits-Filho R; BRAZPD Investigators: Characterization of the BRAZPD II cohort and description of trends in peritoneal dialysis outcome across time periods. Perit Dial Int 2014, in press.
34.
Loghman-Adham M: Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003;9:155-171.
35.
Yoder LA, Xin W, Norris KC, Yan G: Patient care staffing levels and facility characteristics in U.S. hemodialysis facilities. Am J Kidney Dis 2013;62:1130-1140.
36.
Eisenstein EL, Sun JL, Anstrom KJ, et al: Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009;122:170-180.
37.
Li PK, Chow KM: The cost barrier to peritoneal dialysis in the developing world - an Asian perspective. Perit Dial Int 2001;21(suppl 3):S307-S313.
38.
Jung B, Blake PG, Mehta RL, et al: Attitudes of Canadian nephrologists toward dialysis modality selection. Perit Dial Int 1999;19:263-268.
39.
Just PM, de Charro FT, Tschosik EA, et al: Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008;23:2365-2373.
40.
Docteur E, Oxley H: Health-care systems: lessons from the reform experience. OECD Health Working Paper No. 9 (Paris, Organization for Economic Co-operation and Development) 2003.
41.
Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B; REIN Registry: Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrol Dial Transplant 2012;27:2312-2322.
42.
Blake PG: The complex economics of modality selection. Perit Dial Int 2004;24:509-511.
43.
Dor A, Pauly MV, Eichleay MA, et al: End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007;7:73-111.
44.
Horl WH, de Alvaro F, Williams PF: Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: access to ESRD treatments. Nephrol Dial Transplant 1999;14:10-15.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.